Anne Bertolotti

USPTO Granted Patents = 9 (Patent Applications = 2)

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

7 out of 69

United Kingdom Research and Innovation

Medical Research Council

patents

4. 1 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11364211 - Methods for selecting phosphatase selective and non-selective phosphatase inhibitors (2022-06-21),

2. 11337941 - Inhibitors and their uses (2022-05-24),

3. 11331286 - Inhibitors and their uses (2022-05-17),

4. 11154519 - Inhibitors and their uses (2021-10-26),

5. 10954198 - Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases (2021-03-23),

6. 10526297 - Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases (2020-01-07),

7. 10100020 - Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases (2018-10-16),

8. 9682943 - Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases (2017-06-20),

9. 7932422 - Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases (2011-04-26),

Title: Anne Bertolotti: Innovator in Phosphatase Inhibitors

Introduction

Anne Bertolotti is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biochemistry, particularly in the development of phosphatase inhibitors. With a total of nine patents to her name, her work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Among her latest patents is a method for selecting phosphatase selective and non-selective phosphatase inhibitors. This invention discloses a method to discover selective inhibitors of phosphatases. The method involves screening a test compound to determine whether it binds to a holophosphatase selectively or non-selectively. The process includes providing two different holophosphatases, testing the compound's binding ability to each, and comparing the results. Additionally, she has developed inhibitors related to PPP1 R15A and PPP1 R15B, which are useful in treating diseases associated with the accumulation of misfolded proteins.

Career Highlights

Anne has worked with notable organizations such as United Kingdom Research and Innovation and Inflectis Bioscience. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Some of her coworkers include Philippe Guedat and Indrajit Das. Their collaborative efforts have further enhanced the research and development of innovative solutions in the field.

Conclusion

Anne Bertolotti's work in phosphatase inhibitors showcases her dedication to advancing medical science. Her innovative patents and collaborations highlight her significant role in the research community.

This text is generated by artificial intelligence and may not be accurate.